Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANZ 0502 Neo Gem in large operable or locally advanced breast cancer
ACTRN12606000191594Phase 2Terminated
- Sponsor
- Breast Cancer Trials
- Start
- Aug 2006
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of epirubicin, cyclophosphamide, docetaxel, gemcitabine and trastuzumab in breast cancer, sponsored by Breast Cancer Trials. Primary endpoints: Pathologic complete response in HER2-non-overexpressing breast cancer and Pathologic complete response in HER2-overexpressing breast cancer. Started Aug 2006; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12606000191594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000191594.